In late 2026, the industry is pivoting toward "Subcutaneous Bevacizumab Biosimilars." This year, a radical new class of "High-Concentration Formulations" is being used to deliver the drug via a simple under-the-skin injection rather than a multi-hour IV drip. Using data from these "Injection-vs-Infusion" studies, the Biosimilar Bevacizumab Market is reducing the time a patient spends in a...
English
French
Spanish
Portuguese
Deutsch
Turkish
Dutch
Italiano
Russian
Romaian
Portuguese (Brazil)
Greek